Oppenheimer Upgrades Biogen (BIIB) Following Strong BG-12 Trial Data, Q1 Earnings

An analyst at Oppenheimer just upgraded shares of Biogen (NASDAQ: BIIB) from Underperform to Perform in a mid-day research note. The firm suspended its $62 price target.

Thursday's upgrade follows Q1 earnings from the company earlier. Additionally, and likely more importantly, Biogen announced strong results from a trial of its BG-12 multiple sclerosis pill.

Biogen shares last traded at $102.82, up 18.7 percent from Wednesday's closing price.

For more ratings news on Biogen click here and for the rating history of Biogen click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
• Amboss Opens Affiliate Program: Earn Recurring Bitcoin Commissions by Growing Bitcoin Payments